Skip to main content
Vasomotor symptoms Getty Images 1477775902
ABSTRACT & COMMENTARY

Targeting Vasomotor Symptoms with a Neurokinin-3 Receptor Antagonist

A meta-analysis of five randomized controlled studies showed that fezolinetant improved moderate-to-severe vasomotor symptoms with a pooled mean difference of 2.62 episodes per day (95% confidence interval [CI], 1.85-3.41) and had no significant adverse effects compared to placebo (odds ratio, 1.01; 95% CI, 0.84-1.22).